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 Introduction 
 Behçet’s disease (BD) is a refractory, systemic infl am-
matory disease characterized by four main symptoms: 
oral aphthous ulcers, ocular lesions, skin lesions, and gen-
ital ulcers. It is occasionally responsible for infl ammation 
in tissue and organs throughout the body including the 
vascular system, central nervous system, gastrointestinal 
tract, lungs, kidneys, and joints  [1] . The etiology of BD is 
unknown and BD is seen most frequently among Turkish, 
Israeli and Japanese populations. It has been claimed that 
immunologic abnormalities triggered by microbial agents 
or environmental factors in genetically susceptible indi-
viduals play an important role in the development of this 
disease  [2] . Vascular injuries, hyperfunction of neutro-
phils, and autoimmune responses are also signifi cant 
characteristics of BD  [3] , but the clinical features of BD 
differ from those of classic autoimmune diseases  [4] . It 
has been shown that in BD endothelial damage could oc-
cur as a result of different immunological abnormalities 
 [5] . 
 Angiotensin-converting enzyme (ACE) has been iden-
tifi ed as a membrane-bound enzyme in several types of 
cells, including vascular endothelial cells, various absorp-
tive epithelial cells, neurons, macrophages, and T lym-
phocytes. It is also present in a circulating form, produced 
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 Abstract 
 Objective: To investigate a potential relationship be-
tween I/D polymorphism within intron 16 of the angio-
tensin-converting enzyme (ACE) gene located on human 
chromosome 17 and Behçet’s disease.  Materials and 
Methods: Genomic DNA was obtained from 35 Turkish 
patients diagnosed with Behçet’s disease according to 
the International Study Group criteria and 150 healthy 
individuals. Polymerase chain reaction was used to de-
tect the presence of I and D (insertion and deletion) al-
leles in intron 16 of the ACE gene in these DNA samples. 
 Results: We found differences in ACE I/D polymorphism 
between Behçet’s disease and healthy controls (   2  = 4.61, 
d.f. = 1, p = 0.044). In Behçet’s disease patients, the D al-
lele frequency was 84.3% and I allele frequency 15.7%. 
 Conclusion: An association between Behçet’s disease 
and ACE polymorphism may provide a useful basis for 
future molecular studies and therapeutic approaches in 
this complex disease. 
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by vascular endothelial cells, in biological fl uids such as 
plasma. The levels of tissue and circulating ACE activities 
are under tight genetic control  [6] . The ACE gene is lo-
cated on chromosome 17 and shows polymorphism that 
is characterized by the presence of a 287-base pair alu 
repeat within intron 16  [7] . The presence of the extra frag-
ment is associated with lower circulating and tissue ACE 
activity, and this variant of the ACE gene is termed the 
insertion (or I) allele. The absence of this fragment (dele-
tion or D allele) is associated with relatively higher ACE 
activity  [8] . The allelic frequency of the ACE gene varies 
among different racial and ethnic groups  [9, 10] . 
 This study aimed to evaluate the possible role of the 
ACE I/D polymorphism in BD. 
 Subjects and Methods 
 Genomic DNA from 35 Turkish patients (23 male, 12 female), 
diagnosed with BD according to the International Study Group 
criteria, and 150 healthy individuals (97 male, 53 female) was pre-
pared from peripheral blood samples by a standard phenol/chloro-
form extraction method  [11] . Polymerase chain reaction (PCR) was 
used to detect the presence of I and D alleles in intron 16 of the 
ACE gene according to the method described by Rigat et al.  [8] us-
ing an upstream primer 5  -CTGGAGACCACTCCCATCCTTTCT-
3  and downstream primer 5  -GATGTGGCCATCACATTCGT-
CAGAT-3  . Amplifi cation was performed for 35 cycles with dena-
turation, extension and annealing temperatures of 94, 60 and
72  °  C, respectively. Amplifi ed fragments (490 bp for the I allele
and 190 bp for the D allele) were separated by 2% agarose gel elec-
trophoresis and identifi ed using the UVI Gel Documentation 
 system. 
 Conformity with the Hardy-Weinberg equilibrium for genotype 
distribution was estimated by    2  test. A value of p  ! 0.05 was con-
sidered statistically signifi cant. All statistical analyses were carried 
out using the SPSS 10.0 computer program (Statistical Package for 
Social Sciences, SPSS Inc.). 
 Results 
 Electrophoretic identifi cation of the alleles according 
to their PCR product length is shown in  fi gure 1 and ge-
notype and allele frequencies are given in  table 1 . In BD 
patients the D allele was seen in 59 alleles out of 70 chro-
mosomes corresponding to an allele distribution of 
84.3%, and the I allele in 11 chromosomes (15.7%). Dif-
ferences in DD, ID and II genotypes did not show sta-
tistical signifi cance between the BD patients and con-
trols. However, D and I allele frequencies showed sta-
 Fig. 1. Electrophoretic analysis of PCR 
products demonstrating genetic (I/D) 
polymorphism of ACE in BD: DD 
(lanes 1, 2, 4, 5, 7, 8), ID (lanes 3, 9), 
II (lanes 6), M (marker, 100-bp lad-
der). 
Table 1. Distribution of ACE I/D polymorphism in BD and normal subjects
Subjects ACE genotypes ACE alleles
DD ID II D I
n % n % n % n % n %
Controls (n = 150) 87 58 44 29.3 19 12.7 218 72.7 82 27.3
BD (n = 35) 26 74.3 7 20 2 5.7 59 84.3 11 15.7
2 = 3.19, d.f. = 1, p = 0.074 2 = 4.61, d.f. = 1, p = 0.044
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tistically signifi cant (p  ! 0.05) differences between the 
BD patients and controls. We did not observe any rela-
tionship of D and I allele frequency and gender in BD 
patients. 
 Discussion 
 BD is a systemic infl ammatory disorder with unknown 
pathogenesis. Although the most common features are 
recurrent oral and/or genital ulcerations, many other sys-
tems such as the gastrointestinal tract, the central nervous 
system, and the skin and blood vessels may be affected. 
The prevalence and incidence of the condition and its 
constituent manifestations show marked variability 
among different populations  [12] . The vascular injuries 
are superimposed on a hypercoagulability that is also 
characteristic of BD and which may be due in part to ac-
tivated endothelial cells and activated platelets   [3] . 
 Extensive expression of adhesion molecules on vascular 
endothelial cells of BD patients was reported recently, sug-
gesting that adhesion molecules might play an important 
role in vasculitis. In addition, plasma endothelin-1 (ET-1) 
concentrations were found to be signifi cantly increased in 
patients with active BD. Elevated ET-1 is the direct result 
of its increased synthesis from injured vascular endothe-
lial cells. Plasma ET-1 levels correlate with disease activity. 
These fi ndings indicate that ET-1 may play an important 
role in the development or progression of vasculitis  [5] . 
 ACE in mononuclear cells may participate in local pro-
duction or degradation of regulatory peptides (for exam-
ple, at the site of infl ammation reactions). Some natu-
rally occurring infl ammatory peptides, such as bradyki-
nin and substance P, are partially inactivated by ACE. 
The renin-angiotensin system (RAS) itself is likely to in-
fl uence cytokine synthesis; interleukin-1-induced cyto-
kine synthesis was increased by approximately 20% in the 
presence of angiotensin II. Like ACE, angiotensinogen 
gene expression is subject to tissue-specifi c hormonal and 
developmental controls. Endocrine RAS activities are as-
sociated with the regulation of vascular tonus and cardiac 
function in the body, while autocrine RAS activities con-
tribute to infl ammation reactions in tissues  [6] . 
 ACE is involved in the conversion of angiotensin I to 
angiotensin II through its metalloproteinase enzymatic 
activity and plays a major role in RAS and kallikrein-ki-
ninogen systems. Angiotensin II increases vascular 
smooth muscle cell contraction and affects smooth mus-
cle proliferation, monocyte adhesion, and platelet adhe-
sion and aggregation  [13] . 
 ACE is attractive as a candidate to play a role in the 
development of vascular pathological states. Evidence 
suggests that the DD genotype increases susceptibility for 
coronary heart disease, myocardial infarction, and both 
diabetic and nondiabetic renal disease  [14] . This enzyme 
plays an integral role in the regulatory system responsible 
for endothelial control and vascular tone, systems that are 
commonly affected in lupus patients  [13] . In addition, it 
has been shown that the circulating level of the ACE is 
approximately twofold higher in individuals homozygous 
for the ACE deletion (D) allele  [8] . An association of the 
D genotype with chronic infl ammation in the bronchiole 
in asthma has been indicated  [6] . In tissues, the produc-
tion of angiotensin I is higher than in plasma (80 vs. 20%). 
Recent studies have shown that control of RAS in tissues 
is independent of levels in circulation. ACE expression is 
closely regulated by dexamethasone, because glucocorti-
coid-responsive elements are located in the ACE promot-
er. These studies indicate multifactorial control of ACE 
expression in tissues  [15] . 
 In this study we investigated the relationship between 
ACE polymorphism and BD. According to these prelimi-
nary observations, BD patients living in Denizli province 
of Turkey show a D allele frequency that is greater than 
that in the general population, representing a statistically 
signifi cant difference (   2  = 4.61, d.f. = 1, p = 0.044). Since 
the ACE genes are functional in physiological control, the 
frequency of the D allele, with concomitant high levels of 
ACE production might contribute to the overall pathogen-
esis of the disease. We postulate that the increased expres-
sion of ACE might be infl uenced by the D allele in non-
endothelial tissues under pathologic conditions, given the 
effect of D alleles on inducible expression of angiotensin 
II during the progress of tissue infl ammation  [16] . 
 Conclusion 
 Our results indicate that in patients with BD, D alleles 
of the ACE gene are present at a higher frequency than in 
the normal Turkish population. Although the number of 
patients in this initial study was limited, we believe that 
the ACE D allele may represent a signifi cant factor in BD. 
We recommend that other factors, such as angiotensin II 
gene polymorphisms and RAS components that may con-
tribute to infl ammation in BD, should also be investi-
gated. This approach should aid progress in the charac-
terization and therapy of this disease. 
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